β-Glycosphingolipids as Mediators of Both Inflammation and Immune Tolerance: A Manifestation of Randomness in Biological Systems

Abstract

Plasticity in biological systems is attributed to the combination of multiple parameters which determine function. These include genotypic, phenotypic, and environmental factors. While biological processes can be viewed as ordered and sequential, biological randomness was suggested to underline part of them. The present review looks into the concept of randomness in biological systems by exploring the glycosphingolipids-NKT cells example. NKT cells are a unique subset of regulatory lymphocytes which play a role in both inflammation and tolerance. Glycosphingolipids promote an immune balance by changing different arms of the immune system in opposing environments. Traditional immunology looks at skewing the immune system into different directions by different types of activation of the same cell stimulation of different cells subsets, use of different ligands, or different the effect of different immune environments. While these may explain some of the effects, the lack of consistency and opposing results under similar settings may involve randomness which may also be part of real life effects of immunomodulatory agents. It means that several of the biological processes, cannot be explained by simple linear models, and may involve more complex concepts. The application for these concepts for improving therapies to patients with Gaucher disease are discussed. SUMMARY The use of different ligands that target a variety of cell subsets in different immune environments may underlie differences in the functionality of NKT cells and their variability in response to NKT-based therapies. The novel concept of randomness in biology means that several biological processes cannot be solely explained by simple linear models and may instead involve much more complicated schemes of random disorder. These may have implications on future design of therapeutic regimens for improving the response to current treatments.

Antibody Response to Severe Acute Respiratory Syndrome‐ Corona Virus 2, Diagnostic and Therapeutic Implications

“…(35) Methods for overcoming resistance by implementing host-tailored variability are being developed based on data generated from the use of these methods for improving the effects of other immunomodulatory drugs. (120)(121)(122)(123) These include implementing artificial intelligence methods for overcoming host compensatory responses in sepsis and its sequel (120) and for improving the effects of adjuvants. (122) Algorithmcontrolled treatment regimens are now being used in several clinical trials for overcoming drug resistance (NCT03843697; NCT03747705).…”

Overcoming Compensatory Mechanisms toward Chronic Drug Administration to Ensure Long-Term, Sustainable Beneficial Effects

“…Transcriptionally diverging genes that control immune functions, including the production of cytokines and chemokines, differ between cells and have distinct promoter structures. 62 , 63 A wide intra-subject variability has been shown in the expression of intracellular nitric oxide in immune cells. 64 This variability has been shown to predict an individual’s immune response to influenza vaccination and is associated with altered antibody levels.…”

“…A dynamic platform, based on signatures of patient-tailored variability, is being developed to ensure the long-term, sustainable beneficial effect of drugs, with minimal toxicity. 4 , 40 , 58 , 63 , 118 The platform is being developed in steps. In the first step, the effect of introducing variability into therapeutic regimens of patients who partially or completely lost their response to chronic medications is evaluated using algorithms that introduce pseudo-random number generators, which introduce variability in times of administration and dosages within an approved range.…”

Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy

“…This phenomenon may partially be related to chronotherapeutic effects. [151][152][153] Whether chronobiology is linked to MT behavior is yet to be determined. 154 Ongoing clinical trials (NCT03843697; NCT03747705) are evaluating effects of introducing variability in patients with inflammatory bowel disease who lost their response to anti-TNFs, and in patients with epilepsy who lost response to anti-epileptics.…”